TRENDING :  Market Movers  |  Top 50   SPY (0.2%)    XTN (0.15%)    UNP (4.36%)    UGAZ (-2.25%)    TYME (-6.18%)    RYAAY (0.83%)    PANW (-1.66%)    PAGS (-9.74%)    ORCL (0.08%)    MU (0.58%)    MJ (-0.62%)    MHK (0.69%)    M (0.49%)    IWM (-0.3%)    GOOGL (0.11%)    GDXJ (-2.03%)    FB (-0.28%)    EWZ (1.03%)    EWW (-0.11%)    CRM (0.42%)    CGC (4%)    BABA (-0.33%)    BA (0.68%)    ATVI (0.74%)    ARCW (-4.94%)

 INCY - Incyte Corporation

$73.96 [-0.36][-0.49%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $100.00
Low $82.00
Average $93.33
Current $73.96

CompanyAnalyst NamePT ActionActionRatingTargetDate
Stifel NicolausAnnouncesInitiates Coverage OnHold$82.0004/11/19
William BlairRaisesUpgradesStrong Buy$100.0001/24/19
*Last 90 days


Service NameTrader NamePosition TypeTarget %Target PriceTarget Date Issue Date
Big PortfolioTraderCZSubscribe12.45 %Subscribe09/23/1809/23/17View

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



No recommendations found.


Relative Strength Alert For Incyte

Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on

Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group

Merck amp Co Inc MRK announced that the FDA granted approval to its blockbuster anti PD 1 therapy Keytruda for an expanded first line lung cancer indication It is now approved as a monotherapy for first line treatment of patients with stage III or metastatic non small cell lung

The Implied Analyst 12-Month Target For AMCA

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the

Concert Pharma Initiates Early-Stage Schizophrenia Study

Concert Pharmaceuticals Inc CNCE announced that it has initiated a multiple ascending dose MAD phase I study on its pipeline candidate CTP 692 a novel deuterium modified form of D serine as an adjunctive treatment for schizophrenia The phase I program now includes three

3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell

InvestorPlace Stock Market News Stock Advice amp Trading Tips Just a day after convincing traders that all is well vis a vis a move to the highest close since October of last year the S amp P 500 threw investors a curveball by falling 0 81 on Tuesday Volume

NASDAQ Composite Index closes up 19.78 points for the week, rising for the 5th straight day

Wednesday s session closes with the NASDAQ Composite Index 46 86 This is the 5th straight day of increase for the index The total shares traded for the NASDAQ was over 2 5 billion Wednesday s session closes with the NASDAQ Composite Index 46 86 This is the 5th straight day of increase for

Wednesday Sector Laggards: Energy, Healthcare

The worst performing sector as of midday Wednesday is the Energy sector showing a 1 7 loss Within the sector Cimarex Energy Co Symbol XEC and Concho Resources Inc Symbol CXO are two large stocks that are lagging showing a loss of 4 5 and 3 6 respectively Among energy ETFs one

Nasdaq 100 Movers: INCY, AMD

In early trading on Wednesday shares of Advanced Micro Devices AMD topped the list of the day s best performing components of the Nasdaq 100 index trading up 9 0 Year to date Advanced Micro Devices registers a 57 9 gain And the worst performing Nasdaq 100 component thus far on

4 Toxic Stocks to Abandon or Sell Short for Solid Gains

Accurate identification of rightly priced stocks is the key to successful investing However in practice overpriced toxic stocks and the correctly priced stocks are intermixed in such a way that it is tough to distinguish between the two Generally overpriced toxic stocks are susceptible